Latest EBS news and sentiment

Emergent BioSolutions repurchases $75 million in senior notes

Emergent BioSolutions Inc. has repurchased $75 million of its 3.875% Senior Unsecured Notes due 2028 for about $68 million, reducing the outstanding balance to $364.7 million. This strategic move aims to strengthen the company's financial profile and maintain flexibility for growth. Emergent plans to monitor market conditions for refinancing the remaining notes and will discuss this at upcoming healthcare conferences.

Emergent BioSolutions receives $24M anthrax vaccine contract

Emergent BioSolutions Inc. has secured a $24 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply its CYFENDUS anthrax vaccine. This contract aims to bolster preparedness efforts against anthrax threats. CYFENDUS, approved by the FDA in July 2023, is a two-dose vaccine for post-exposure prophylaxis in individuals aged 18-65.

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Emergent BioSolutions Inc. has been awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray, effective from October 1, 2026, through September 30, 2029, with an option for a two-year extension. This agreement expands access to the opioid overdose reversal treatment across various federal, provincial, and territorial organizations in Canada. The company emphasizes its commitment to combating the opioid crisis by ensuring broad availability of this life-saving treatment.

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Emergent BioSolutions Q1 Net Income USD 6.8 M

Emergent BioSolutions reported a net income of $6.8 million for the first quarter. This financial update provides key performance indicators for the company during the specified period.

JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS)

JPMorgan Chase & Co. has initiated coverage on Emergent Biosolutions (NYSE:EBS) with an "underweight" rating, joining a mixed analyst outlook for the biopharmaceutical company. Despite the new rating, Emergent Biosolutions saw its stock trade up 2.5% to $4.94. The company's recent quarterly earnings exceeded expectations, but analysts still forecast a full-year loss per share.

Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript

This article provides the transcript from Emergent BioSolutions Inc.'s presentation at the Goldman Sachs Healthcare Conference on June 8, 2026. A company representative highlighted Emergent's unique business model, focusing on biodefense partnerships with governments and producing products for critical threats like smallpox, anthrax, and botulism. The company emphasizes its role in addressing difficult product areas with significant barriers to entry.

Emergent BioSolutions (EBS) Holds Above Support as Shares Slip 0.33% - Volume Oscillator

Emergent BioSolutions faces securities probe after $191M NARCAN impairment and $97M adjusted EBITDA report

Emergent BioSolutions is facing a securities probe by Levi & Korsinsky law firm following a reported $191.3 million non-cash impairment on its NARCAN product and a subsequent decline in its stock. The company's Q2 revenue was $234 million with $97 million in adjusted EBITDA, but the impairment was due to increased competition and pricing pressure. The investigation aims to determine if Emergent BioSolutions misled shareholders regarding its financials and the valuation of its naloxone franchise.

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript

Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts

Emergent Biosolutions Inc. (NYSE:EBS) has received an average "Hold" rating from analysts, with an average 12-month price target of $10.00. The company recently reported better-than-expected quarterly EPS of $0.60 and revenue of $234.3 million, though it posted a negative net margin and analysts anticipate a full-year loss. The stock opened at $4.58, near its 52-week low, and institutional investors have been actively trading its shares.

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G

American Century ETF Trust and its affiliates, including American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research, have reported passive ownership stakes in Emergent BioSolutions Inc. (EBS) common stock via a Schedule 13G filing. The ETF Trust holds 5.2% of outstanding shares, while the affiliated entities each hold 5.4%. The filing clarifies that while various advisory clients have rights to dividends, no single client owns more than 5% of EBS.

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded Emergent BioSolutions (NYSE:EBS) to a "Hold" rating. Despite beating Q2 earnings estimates, the company faces analyst forecasts for a full-year loss, increased competition, and pricing pressure, leading to a significant impairment charge against its NARCAN franchise. The stock currently has a consensus "Hold" rating with an average price target of $10.00, while insider selling and institutional trading activity have also been noted.